Snipr Biome to send first candidate to clinic

The FDA has given Danish CRISPR company Snipr Biome the thumbs-up to begin clinical testing of its drug candidate that targets E. coli infections. A phase I trial is scheduled to begin in the first half of 2022.
Christian Grøndahl, co-founder and CEO of Snipr, can look forward to an exciting year ahead, as the company can begin clinically testing its first development candidate | Photo: EY / PR
Christian Grøndahl, co-founder and CEO of Snipr, can look forward to an exciting year ahead, as the company can begin clinically testing its first development candidate | Photo: EY / PR
by ULRICH QUISTGAARD, translated by daniel pedersen

CRISPR company Snipr Biome has an exciting year ahead, as the US Food and Drug Administration (FDA) has approved the company's application to initiate a phase I clinical trial with the company's first development candidate, SNIPR001, which is designed to target E. coli in the gut, a press release announces.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading